Investment Analysts’ Weekly Ratings Changes for CG Oncology (CGON)

CG Oncology (NASDAQ: CGON) recently received a number of ratings updates from brokerages and research firms:

• 5/19/2026 – CG Oncology is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 5/18/2026 – CG Oncology had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 5/14/2026 – CG Oncology had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $82.00 price target on the stock, up from $77.00.
• 5/11/2026 – CG Oncology had its price target raised by JPMorgan Chase & Co. from $91.00 to $96.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – CG Oncology had its price target raised by Royal Bank Of Canada from $79.00 to $81.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – CG Oncology had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $77.00 price target on the stock, up from $75.00.
• 5/11/2026 – CG Oncology had its price target raised by Wedbush from $77.00 to $80.00. They now have an “outperform” rating on the stock.
• 4/27/2026 – CG Oncology had its price target raised by Royal Bank Of Canada from $73.00 to $79.00. They now have an “outperform” rating on the stock.
• 4/25/2026 – CG Oncology was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/20/2026 – CG Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/17/2026 – CG Oncology had its price target raised by JPMorgan Chase & Co. from $65.00 to $91.00. They now have an “overweight” rating on the stock.
• 4/11/2026 – CG Oncology was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/7/2026 – CG Oncology had its price target raised by HC Wainwright from $80.00 to $100.00. They now have a “buy” rating on the stock.
• 3/28/2026 – CG Oncology was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 15,600 shares of the firm’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director directly owned 15,600 shares of the company’s stock, valued at $1,138,956. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.80% of the company’s stock.

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.